What is NSCLC Phase 2 Poziotinib?

Category: Others


NCT03318939 is a phase 2 is a open-label, multicenter study of the efficacy and the safety/tolerability of poziotinib in subjects with non-small cell lung cancer, locally advanced or metastatic, with EGFR or HER2 exon 20 insertion mutation.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 1
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with NSCLC Phase 2 Poziotinib

Side effect Patients
Hair loss 1
Leg cramps at night 1
Rashes (redness, swelling) 1
Weight loss 1


Based on patients currently using NSCLC Phase 2 Poziotinib

Dosage Patients
14 mg daily 1


Currently using NSCLC Phase 2 Poziotinib

Duration Patients
1 - 6 months 1
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 0
Last updated:
There are no evaluations for NSCLC Phase 2 Poziotinib.